NPR Health - Shots
FEBRUARY 5, 2023
After months of eye-popping prices, egg lovers are finally seeing some relief. Wholesale prices in the Midwest fell by 58 cents at the end of January, but the days of a $1.50 a dozen may not return.
STAT News
FEBRUARY 5, 2023
As a doctor, I have dedicated my life to saving the lives of others. But as a gay doctor, I have long been unable to do one simple thing that saves lives: donate blood. For more than 30 years, policies in the United States have banned gay and bisexual men from donating blood. That could change — ending decades of discrimination — if the Food and Drug Administration’s newly announced proposal for blood donation is made permanent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NPR Health - Shots
FEBRUARY 5, 2023
Send leaders into space for perspective, tap solar power to offer electricity for all, make "dignity" a priority — those are some of the wishes readers have for 2023.
Medical Xpress
FEBRUARY 5, 2023
Maryland officials are preparing for as many as 80,000 residents who could no longer qualify for Medicaid coverage this spring, as the federal government reinstates a requirement that existed before the COVID-19 pandemic for states to verify the eligibility of recipients.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
JAMA Internal Medicine
FEBRUARY 5, 2023
This cross-sectional study examines the death rates among active and nonactive physicians aged 45 to 84 years.
Medical Xpress
FEBRUARY 5, 2023
Taking vitamin D supplements does not reduce the risk of asthma attacks in children or adults, according to an updated Cochrane Review.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
FEBRUARY 5, 2023
The Swiss pharma’s CDK4/6 inhibitor reduced risk for recurrence by 25% when added to the standard-of-care endocrine therapy, inviting comparisons to Lilly’s Verzenio.
JAMA Internal Medicine
FEBRUARY 5, 2023
This prospective cohort study investigates the association between healthy lifestyle factors prior to SARS-CoV-2 infection and risk of post–COVID-19 condition.
BioSpace
FEBRUARY 5, 2023
Follow updates from the American Society of Clinical Oncology 2023 annual meeting—BioSpace will be tracking key updates here throughout the conference. All times are Eastern Standard.
Roots Analysis
FEBRUARY 5, 2023
Modified T-cell receptors or TCR therapies is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Structurally, TCR is a heterodimer comprising of two different polypeptide chains, namely the α-chain and β-chain. TCR therapies’ tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
FEBRUARY 5, 2023
ADCs from BioNTech, Daiichi Sankyo and Merck are the subject of high-profile abstracts featured at the oncology meeting, along with Merck’s late-breaking Phase III non-small cell lung cancer data.
FDA Law Blog
FEBRUARY 5, 2023
By Faraz Siddiqui — In the Spring of 2021, the Health Resources and Services Administration (HRSA) threatened six drug companies with billions of dollars in penalties for not providing 340B discounts to covered entities that sell drugs through vast networks of contract pharmacies (more background on earlier posts ). The drug makers argued that their statutory obligation to provide discounts did not extend to multiple contract pharmacies, who they said often abused the system.
BioSpace
FEBRUARY 5, 2023
The company's Humira biosimilar Yusimry will launch in July with a $995 list price. Mark Cuban’s online pharmacy will sell it at a list price of $569.27 plus fees.
JAMA Internal Medicine
FEBRUARY 5, 2023
This randomized clinical trial examines the safety and efficacy of reducing or stopping medications among inpatients 50 years or older.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
FEBRUARY 5, 2023
Grail, the blood testing company, explores the potential of its commercial blood test, Galleri, in detecting cancer symptoms.
Drug Patent Watch
FEBRUARY 5, 2023
NEXAVAR (sorafenib tosylate) Bayer hlthcare Patent: 8,618,141 Expiration: Feb 11, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of February 5, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
FEBRUARY 5, 2023
The company’s aztreonam-avibactam matched the cure rate of a meropenem-based regimen in patients with drug-resistant infections.
Drug Patent Watch
FEBRUARY 5, 2023
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
FEBRUARY 5, 2023
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Trodelvy (sacituzumab govitecan-hziy) to treat unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer adult patients. Trodelvy has been approved for HR+/HER2- breast cancer adult patients who have previously received endocrine-based therapy and a minimum of two additional systemic therapies
Expert insights. Personalized for you.
134 
Let's personalize your content